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Introduction
Epidemiologic studies show an inverse relationship between
high-density lipoprotein (HDL) cholesterol and cardiovascu-
lar diseases (CVDs),1 but despite improved diagnostic tech-
niques, the atherosclerosis-related clinical burden is still
raising.2 Due to its antioxidant, anti-inﬂammatory, anti-
apoptotic and anti-thrombotic properties, HDL represents
a major anti-atherogenic factor beyond its reverse choles-
terol transport effect3 as it prevents atheroma formation and
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Abstract Quantitative and qualitative defects of high-density lipoprotein (HDL) are important in
atherogenesis. In this study, we investigated whether antibodies against HDL compo-
nents had additional value to conventional cardiovascular risk factors for the diagnosis
of ischaemic stroke (IS) and coronary artery disease (CAD). Cross-sectional study was
conducted on 53 patients with IS, 51 with CAD and 55 healthy controls, and in vitro
studies to validate ﬁndings of the clinical study.We determined serum immunoglobulin
G (IgG) antibodies against HDL (aHDL), apolipoproteins (aApoA-I, aApoA-II and aApoC-I)
and paraoxonase-1 (aPON1) as well as PON1 activity (PON1a), total antioxidant
capacity and biomarkers of endothelial activation (serum nitric oxide metabolites, 3-
nitrotyrosine, VCAM-1 and ICAM-1); in vitro assays tested the capacity of IgG aHDL
puriﬁed from high titer patients to inhibit PON1a and to reverse protective effect of
HDL on endothelial cells. IgG aHDL, aApoA-I and aPON1 were higher in IS and CAD than
controls (p < 0.001), predicted negatively PON1a and positively VCAM-1 and ICAM-1.
By adding IgG aHDL and aApoA-I to a traditional cardiovascular risk factors model for IS
and by adding IgG aHDL in a similar model for CAD, we obtained better discrimination
of IS and CAD from healthy controls. IgG aHDL puriﬁed from IS and CAD inhibited
PON1a by 38% (p < 0.01) and abrogated the protective effect of HDL on VCAM-1
expression by 126% compared with non-speciﬁc human IgG (p < 0.001). IgG against
HDL components interfere with the antioxidant and anti-inﬂammatory properties of
HDL and may represent novel biomarkers for vascular disease that need to be
investigated in prospective studies.
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stabilizes plaques, preventing rupture and thrombosis.4 HDL
has a very complex protein and lipid structure and its plasma
concentration does not necessarily correlate to these protec-
tive effects, leading to the concept of HDL dysfunction.5
Despite increasing plasma HDL, cholesteryl ester transfer
protein inhibitors6,7 and niacin8,9 failed to achieve their
expected clinical outcomes.
We previously identiﬁed immunoglobulin G (IgG) anti-
bodies against HDL (aHDL), more speciﬁcally anti-apolipo-
protein A-I antibodies (aApoA-I) in patients with
autoimmune diseases, in association with decreased para-
oxonase-1 activity (PON1a), enhanced endothelial activa-
tion, heightened disease activity and CV damage.10–13Others
have recently described IgG anti-PON1 (aPON1) antibodies in
patients with rheumatoid arthritis,14 systemic lupus erythe-
matosus (SLE)15 and also in patients with primary anti-
phospholipid syndrome.16
Anti-ApoA-I antibodies have been identiﬁed also in non-
autoimmune patients with atherosclerosis-associated clinical
events17–19: in particular, IgG aApoA-I antibodies are asso-
ciated with atherosclerotic plaque vulnerability in patients
with acute coronary syndrome,20 behaving as independent CV
prognostic marker of major CV events after myocardial infarc-
tion21 andpredictingworse post-stroke outcomes.18 Likewise,
we found aApoA-I antibodies in type 2 diabetes,22 particularly
in patients with diabetes complicated with CVD.23 Further-
more, we recently reinforced the clinical relevance of ApoA-I
antibodies in a phase II, randomized, placebo-controlled, trial
with niacin showing that the raise inHDL-C achievedbyniacin
was hampered by an increase in aApoA-I antibodies, suggest-
ingapossible explanationwhy theHDL-C-boosting treatments
fail to reduce CVD risk.24
Herein, we investigated whether antibodies against the
HDL complex added diagnostic value to conventional CV risk
factors and evaluated their biologic effects on the antioxidant
and anti-inﬂammatory properties of HDL.
Materials and Methods
Study Participants
One hundred and twelve consecutive patients (56 ischaemic
stroke [IS] and 56 coronary artery disease [CAD]) with
atherosclerosis-associated clinical events recruited at the
Internal Medicine outpatients clinic of Fernando Fonseca
Hospital in Portugal were invited to participate in this cross-
sectional case–control study. Inclusion criteria were: at least
one vascular event conﬁrmed by computed tomography (CT)
scan (IS) or coronary angiography (CAD) in the past 5 years,
without evidence of active systemic inﬂammation (normal
erythrocyte sedimentation rate [ESR] and high-sensitivity
C-reactive protein [hsCRp] < 1.0 mg/dL) and routine (six-
monthly) follow-up appointments.
Exclusion criteria were: infection, cancer, renal or hepatic
dysfunction (serum creatinine < 1.2 mg/dL and aspartate
transaminase/alanine transaminase [ALT/AST] < 2 refer-
ence value), decompensated cardiac insufﬁciency and any
thrombotic event in the previous 3 months. Of the initial
cohort, 5 patients did not have conﬁrmed CAD and 3 patients
had a cerebral haematoma rather than IS andwere excluded.
Therefore, the study enrolled 51 patients with CAD and
53 with IS.
Fifty-ﬁve healthy subjects without known CVD or cere-
brovascular disease and not taking any medication were
recruited during the same time via various advertising
means including internal email or direct invitations to staff
and patients’ relatives. Demographic data of patients and
controls and medical history, including current medication
data, are summarized in ►Table 1.
All subjects signed consent forms approved by the ethics
committees of the hospital and the study was performed
according to the revised Declaration of Helsinki. Blood
samples were collected after a 12-hour fast and were cen-
trifuged at 3,000  g at 4°C for 10 minutes to obtain serum,
which was kept at –80°C until assayed.
Measurement of Antibodies against HDL and its
Components
Titers of IgG aHDL, aApo A-I, aApo A-II, aApo C-I, aPON1 and
immunoglobulin M (IgM) aHDL antibodies were assessed by
in-house enzyme-linked immunosorbent assays (ELISAs).
IgG aHDL and IgG aApoA-I antibodies were measured as
previously described11–13,24; ELISA testings for the others
antibodies were also adapted from these studies. Brieﬂy, the
antigen (HDL or other HDL component) solution was pre-
pared at the appropriate concentration (20 µg/mL human
HDL, 10 µg/mL human ApoA-I or ApoA-II, 2 µg/mL human
ApoC-I [Sigma-Aldrich, Portugal] and 1 µg/mL PON1 [Abnova,
Tebu-bio, Portugal], respectively) in 70% ethanol or bicarbo-
nate (BIC) buffer (pH 9.8) for PON1, and coated to a half 96-
well micro-titer plates for a period of 2 hours at 37°C. The
plates were then blocked with the addition of 100 μL/well at
1% bovine serum albumin (BSA)—10 mM phosphate buffer
saline (PBS) (pH 7.4) for 1 hour at 37°C. The unbound
blocking agent was then removed and the plates were
washed 4 with PBS. Next, standard, positive and negative
controls and samples were diluted (1:100 for IgG and IgM
aHDL, aApoA-II, aApoAC-I; 1:200 for IgG aApoA-I and 1:300
for IgG aPON1) in blocking buffer and added in duplicate to
each half of the plate for 1 hour at 37°C. The unbound
antibodies were removed by repeating the washing step.
Alkaline phosphatase conjugated anti-human IgG (1:1,000 in
the blocking agent) or anti-human IgM (1:15,000 in the
blocking agent) was added for 1 hour. Plates were then
washed 2 with PBS and 2 with BIC buffer. P-nitrophenyl
phosphate diluted in BIC buffer was added and incubated at
37°C for colour development, and the absorbance read by a
Biotrak II plate reader (Amersham Biosciences) at 405 nm
after 1 hour.
All assayswerevalidatedby the inclusion of internal quality
control samples of known activity and the results were
calculated after subtraction of the background in the uncoated
half of the plate. IgG aApoA-I antibodies were expressed as
μg/mLdeterminedby thestandard curve present in eachplate.
This curvewaspreparedwith six standards of commercial Apo
A-I antibody (MIA 1404, Thermo Scientiﬁc) in a concentration
range of 0.001 to 0.04 μg/mL. For all the other antibodies (IgG
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aHDL, aApoA-II, aApoC-I, aPON1 and IgM aHDL), the results
were expressed as a percentage of the different positive
control corresponding to 100% for each antibody assay.
Inter-/intra-plate coefﬁcients of variation were less than
10%. The cut-off for the upper normal titers of all antibodies
quantiﬁed in the study was set at the mean  3 standard
deviation (SD) of the control group.
Quantiﬁcation of the Lipid Proﬁle
The plasma lipid proﬁle (total cholesterol, HDL-C, LDL-C and
triglycerides) was determined by standard colorimetric
enzymatic techniques (commercial kits by Randox, Irlandox,
Portugal).
Quantiﬁcation of Paraoxonase 1 Activity (PON1a) and
Total Antioxidant Capacity
Serum PON1a was assessed by quantiﬁcation of nitrophenol
formationby spectrophotometryaspreviouslydescribed.11–13
Total antioxidant capacity (TAC) was assessed using an ABEL-
41M2 antioxidant test kit with Pholasin (Knight Scientiﬁc),
according to the manufacturer’s instructions. An Anthos
Zenyth 1100/3100 multimode detector was used and the
resultswere expressed invitamin E analogue (VEA) equivalent
units (µM)derived fromasetof standardsrunat thesametime.
Quantiﬁcation of Nitric Oxide Metabolites and
3-Nitrotyrosine (3-NT)
Serum nitric oxide metabolites nitrite (NO2-) and nitrate
(NO3-) were measured using a modiﬁed Griess reaction.25
Serumwere diluted in ice-cold ethanol (1:3, v/v), vortex for 1
minute and incubated on ice for 30 minutes after being
centrifuged at 12,000  g for 20 minutes at 4°C and the
supernatants were collected for NO2- and NO3- assessments.
The assay was performed in a standard ﬂat-bottomed 96-
well plate for simultaneous measurement of nitrite and
nitrate concentration. Note that 50 µL of standard or diluted
sample were added in duplicate, and PBS was used as blank.
In half plate, 6.3 U/L of nitrate reductase (Sigma-Aldrich) and
550 µmol/L of nicotinamide adenine dinucleotide phosphate
(NADPH) (Sigma-Aldrich) were added for the reduction of
Table 1 Demographic characteristics and medical history of the healthy controls and patients with atherosclerosis-associated
clinical events
Characteristicsa Healthy controls
(n ¼ 55)
IS (n ¼ 53) p-Valueb CAD (n ¼ 51) p-Valuec
Age, y 57.50 (54.00–79.25) 75.00 (64.00–79.50) < 0.001 82.00 (77.00–86.00) < 0.001
Male sex, n 27(49.10) 32 (60.40) 0.253 22 (43.10) 0.564
BMI, kg/m2 22.45 (21.88–24.78) 24.22 (22.12–25.55) 0.373 25.22 (23.44–26.12) 0.490
Systolic BP, mm Hg 128.00 (121.10–141.50) 147.08 (120.30–164.50) 0.318 119.50 (103.80–139.30) 0.171
Diastolic BP, mm Hg 76.40 (61.00–82.00) 79.00 (68.50–92.50) 0.548 62.00 (56.50–83.50) 0.341
Risk factors, n (%)
Hypertension 0 34 (64.15) < 0.001 36 (70.59) < 0.001
Type 2 diabetes 0 11 (20.75) < 0.001 14 (27.46) < 0.001
Dyslipidaemia 0 11 (20.75) < 0.001 11 (21.57) < 0.001
Smoking 0 7 (13.21) 0.006 9 (17.65) < 0.001
Medication, n (%)
ACE inhibitor 0 7 (13.21) 0.006 12 (23.53) < 0.001
ARB 0 2 (3.77) 0.238 2 (3.92) 0.229
β-blocker 0 5 (9.43) 0.026 7 (13.73) 0.005
Calcium-
channel blocker
0 4 (7.55) 0.055 7 (13.73) 0.005
Diuretics 0 9 (16.98) 0.001 14 (27.46) < 0.001
Anti-platelet
agents
0 12 (22.64) < 0.001 13 (25.90) < 0.001
Statin 0 5 (9.43) 0.026 9 (17.65) <0.001
Abbreviations: ACE, angiotensin-converting enzyme; ANOVA, analysis of variance; ARB, angiotensin receptor blocker; BMI, body mass index; BP,
blood pressure; CAD, coronary artery disease; IS, ischaemic stroke.
aAll continuous variables are reported as median with interquartile range (IQR) and categorical variables were presented as frequencies (n) and
percentages (%).
bComparison between healthy control and ischaemic stroke (IS) group. p-Value obtained by one-way ANOVA applied to log-transformed data or
Fisher’s exact test as appropriate.
cComparison between the healthy control and coronary artery disease (CAD) group. p-Value obtained by one-way ANOVA applied to log-transformed
data or Fisher’s exact test as appropriate.
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nitrate to nitrite. After 2 hours, the plate was incubated at
room temperature, and Griess reaction was initiated by
adding equal volumes of 2% sulphanilamide (Sigma-Aldrich)
in 5% H3PO4 and 0.2% N-(1-naphthyl)-ethylenediamine dihy-
drochloride (Sigma-Aldrich) inwater, mixed just prior to use.
After 10 minutes of incubation at room temperature, the
absorbance was read at 540 nm and the levels were
expressed as μM. Serum levels of 3-NT were determined by
enzyme immunoassay using commercial kits (Oxis Research,
Foster City, California, United States), according to the man-
ufacturer’s instructions.
Measurement of Soluble Endothelial Cell Adhesion
Molecules
Soluble intracellular adhesion molecule (ICAM-1) and vas-
cular cell adhesion molecule (VCAM-1) levels were deter-
mined by ELISA using commercial kits (R&D Systems,
Citomed, Portugal), according to the manufacturer’s
instructions.
Isolation of the aHDL Antibodies by Immunoafﬁnity
Chromatography
Anti-HDL antibodies from patient’s serum were isolated by
immunoafﬁnity chromatography, and human HDLwas cova-
lently coupled to N-hydroxysuccinimide (NHS)-activated
HiTrap afﬁnity column of 1 mL (GE Healthcare) according
to the manufacturer’s instructions. Brieﬂy, HDL (10 mg) was
dissolved in coupling buffer (0.2 M NaHCO3, 0.5 M NaCl, pH
8.3). The column was embedded in isopropanol to preserve
the stability of the activated medium, and immediately prior
to the coupling of the ligand, the columnwasﬂushedwith six
columnvolumes of ice-cold 1 mMHCl using a 1mL syringe at
a ﬂow rate of 1 mL/min (½ drop/s). Once completed, the
ligand solution was added onto the column that was sealed
and left to stand for 30 to 60 minutes at room temperature.
Then, to deactivate any excess active groups that did not
couple to the ligand and to wash out the non-speciﬁcally
bound HDL, the column was washed with six column
volumes of 0.5 M ethanolamine, 0.5 M NaCl (pH 8.3) (buffer
A) followed by six column volumes of 0.1 M acetate, 0.5 M
NaCl (pH 4) (buffer B) then again with the same volume of
buffer A, after which the column was sealed and allowed to
stand for 30minutes at room temperature. Then, the column
was re-washed with six volumes of buffer B, followed by
buffer A, and then by buffer B again at the end of which the
columnwaswashedwith 0.01 MNaH2PO4, 0.0027 MKCl and
0.137 mM NaCl (pH 7.4). After this step, the column was
ready for use. If not used immediately, it was stored by
applying a storage buffer consisting of 0.05 M Na2HPO4, 0.1%
NaN3 (pH 7).
Before applying the sample, the column was equilibrated
with 10 column volumes of binding buffer (0.02 M Tris, pH
7.5). Serum samples from patients with CAD and IS were
pooled after being selected according to the highest immu-
noreactives previously observed, diluted in equal volume of
binding buffer and ﬁltered through Millex GV 0.22 μm. Then,
the diluted serum was applied to the column and run
through at least six times at room temperature. The unbound
antibodies were removed by washing the column with 10
column volumes of 0.02 M Tris (pH 7.5) and further by 10
volumes of 0.02 M Tris and 0.5 mMNaCl (pH 7.5). Antibodies
retained by the immunosorbent were eluted with 0.1 M
glycine pH 2.5 into tubes containing 70 μL neutralization
buffer (Tris 1 M, pH 8.8). After elution of antibodies at low
pH, the column should bewashedwith 10 volumes of 0.02 M
Tris pH 8.8 and thenwith 10 volumes of 0.02 M Tris pH 7.5 to
re-equilibrate the column. Absorbance (280 nm) of the
collected fractions (1 mL) was measured, and the peak
fractions were dialyzed against PBS and tested for the pre-
sence of aHDL antibodies by ELISA as described above. The
fractions positive for antibodies were pooled, concentrated
by evaporation under nitrogen and stored at –4°C until their
biologic activity was tested.
Inhibition of Paraoxonase 1 Activity (PON1a) by the
Antibodies Isolated from Patient’s Serum
Dose-dependent inhibition assays of PON1awere performed
by incubating human HDL (100 μg/mL) with PBS (basal) or
the aHDL antibodies isolated from patients. As control, we
used irrelevant human IgG (Sigma-Aldrich) at the same
concentration of the fractions tested. After 1 hour of incuba-
tion, PON1a was assessed as described above. All experi-
ments were run in triplicate and results were expressed as a
percentage of the effect on PON1a in basal conditions.
In Vitro Effect of aHDL Antibodies on Cytokine-Induced
Expression of VCAM-1 Levels in Human Umbilical Vein
Endothelial Cells (HUVECs)
Conﬂuent monolayers of HUVECs seeded in 24-well tissue
culture plates were incubated for 16 hours at 37°C in 5% CO2,
in EGM Media (Lonza) supplemented with 10% fetal bovine
serum (FBS) (basal), human HDL (1.0 mg/mL) alone or with
aHDL antibodies (50 μg/mL) isolated frompatient’s serum, or
a non-speciﬁc human IgG (50 μg/mL) or commercial human
ApoA-I monoclonal antibody (MIA 1404) (30 μg/mL). After
being washed, cells were incubated for a further 4 hours in
the basal or stimulated state with 10 ng/mL of tumour
necrosis factor-α (TNF-α). After washing with PBS, cells
were gently trypsinized (0.5% trypsin, ethylenediaminete-
traacetic acid [EDTA]). Trypsinwas neutralizedwith cold PBS
and cells were centrifuged for 5 minutes at 1,200  g. Cell
pellets were suspended and incubated with Fc block (BD
Biosciences) for 10minutes at 4°C following the stainedwith
ﬂuorescein isothiocyanate (FITC)-conjugated anti-human
VCAM-1 (R&D Systems) for 30 minutes on 4°C. After incuba-
tion, cells were washed once with cold PBS and re-sus-
pended. Expression of VCAM-1 was measured as mean
ﬂuorescence intensity (MFI) in a FACS Canto II cytometer.
Ten thousand cells were analysed per sample by using the
Cell Quest Software. Data were expressed as the percentage
of basal VCAM-1 expression positive cells. All experiments
were done in triplicate.
Statistical Analysis
An exploratory analysis was performed for all variables.
Categorical data were expressed as frequencies (n) and
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percentages (%), and continuous variables as median and
interquartile range (25th–75th percentile). For quantitative
variables, the comparison between healthy controls, IS and
CAD groups was performed by one-way analysis of variance
(ANOVA) and Dunnett’s test for multiple comparisons was
applied to log-transformed data (due to the existence of
outliers and skewed distributions). To study the association
between categorical variables, non-parametric Fisher’s exact
test was used. The relationship between HDL levels and the
titers of IgG aHDL, IgG aApoA-I and aPON1antibodies was
evaluated by Spearman’s correlation coefﬁcient. Positive
antibody titer cut-off was deﬁned as mean plus 3 SDs of
healthy subjects, and was used to dichotomize (positive vs.
negative) IgG aHDL, aApoA-I and aPON1 antibodies. Chi-
square test was used to compare the prevalence of positive
antibodies titers between both patients’ groups and controls.
Linear regression models were applied to study the associa-
tion between the resulting binary independent variables and
PON1a, VCAM-1, ICAM-1 and NO2- levels as dependent
variables. Normality assumption of the residualswas veriﬁed
using the Kolmogorov–Smirnov goodness-of-ﬁt test with
Lilliefors correction and logarithmic transformation of
PON1a, VCAM-1, ICAM-1 and NO2- levels was performed
for the violation of the normality assumption.
Logistic regression models were ﬁtted to the data to
evaluate the incremental value to the performance of a
traditional CV risk factors model (reference model) after
adding antibodies against HDL complex to themodel. Results
are presented as odds ratio (OR) and corresponding 95%
conﬁdence intervals (95% CIs). The calibration of the models
was analysed byHosmer–Lemeshowgoodness-of-ﬁt test and
their discriminative ability was measured by the area under
the receiver operating characteristic (ROC) curve. A value of
0.50 is obtained when a model discriminates no better than
chance, and a value of 1.0 means perfect discrimination. The
Hosmer–Lemeshow test compares observed and expected
frequencies of patients and healthy subjects based on the
values of the estimated probabilities obtained by the logistic
regression model. In this test, a high p-value indicates that
the model is performing well, i.e., there is not a large
discrepancy between observed and expected frequencies.
A signiﬁcance level of α ¼ 0.05was considered. All datawere
analysed using STATA 13.0. (StataCorp. 2013, Stata Statistical
Software: Release 13; StataCorp LP, College Station, Texas,
United States) and the Statistical Package for the Social
Sciences for Windows 21.0 (IBM Corp. Released 2012. IBM
SPSS Statistics for Windows; IBM Corp., Armonk, New York,
United States).
Results
Comparative Clinical Features of Participants
Demographic characteristics, clinical features and medica-
tion use of all participants of this study are shown in
►Table 1. IS/CAD participants were older than controls
(p < 0.001) and were more likely to have hypertension
(64%/71%), type 2 diabetes (21%/27%) and dyslipidaemia
(21%/22%) than controls.
Comparative Lipid Proﬁle of Participants
HDL was lower in both patient groups than healthy controls
(p < 0.001). Total cholesterol was similar across groups,
whereas LDL was higher in patients with IS (p ¼ 0.001)
and triglycerides higher in both disease groups (p < 0.001
and p ¼ 0.03, for IS and CAD, respectively) (►Table 2).
Comparative HDL Auto-Antibody Proﬁle and other
Laboratory Variables
Mean IgG aHDL, aApoA-I and aPON1 titers were higher in
both patient groups comparedwith healthy controls (►Fig. 1
A–C; p < 0.001). IgG aHDL titer was positive in 32% (95% CI,
20–46%) of IS patients (17/53) and in 33% (95% CI, 21–48%) of
CAD patients (17/51); IgG aApoA-I was positive in 42% (22/
53, 95% CI, 28–56%) and 33% (17/51, 95% CI, 21–48%) of IS and
CAD patients, respectively; IgG aPON1 was positive in 9% (5/
53, 95% CI, 3–21%) and 23% (12/51, 95% CI, 13–38%) of IS and
CAD patients, respectively. The prevalence of positive anti-
body titers between both patient groups and controls was
signiﬁcantly different (p < 0.001 for IgG aHDL, aApoA-I, and
p ¼ 0.001 for aPON1). No differences were observed for the
remaining antibodies tested.
IgG aHDL directly correlated with the IgG aApoA-I titers
(p < 0.001 in CAD and IS) and IgG aPON1 titers (p < 0.001),
but only in patients with CAD (not shown).
In CAD, four patients presented simultaneous positivity
for aHDL, aApoA-I and aPON1, whereas in IS there were only
three. Ten patients with CAD were double positive (4 aHDL/
aApoA-I and 5 aHDL/aPON1), while in patients with IS 10
were double positive although with a different distribution
(8 aHDL/aApoA-I, 1 aHDL/aPON1 and 1 aApoA-I/aPON1).
Seventeen patients with CAD were positive to one auto-
antibody (4 aHDL, 9 aApoA-I and 3 aPON1), whereas 15
patients with IS were single positive (5 aHDL, 10 aApoA-I).
PON1a was lower in both patient groups compared with
healthy controls (p < 0.001), although TACwas not different
(►Table 2). VCAM-1 and ICAM-1 levels were increased in
both patient groups comparedwith healthy controls (VCAM-
1: p < 0.001 for both; ICAM-1: p ¼ 0.005 and p < 0.001, for
IS and CAD, respectively) (►Table 2). NO2- was decreased in
patients with CAD compared with controls (p ¼ 0.028), but
no signiﬁcant differences were noted for NO3- and 3-NT
levels.
Neither co-morbidities, such hypertension, diabetes mel-
litus and dyslipidaemia, nor treatment modalities affected
mean differences of antibody titers in the patients with CAD
and IS. Despite some negative trends, no correlation was
found between IgG aHDL, IgG aApoA-I, IgG aPON1 and HDL
levels (not shown).
Predictive Value of HDL Auto-Antibody Proﬁle
towards PON1 Activity, VCAM-1 and ICAM-1
Several multiple linear regression models analysed the asso-
ciation of IgG aHDL, aApoA-I or aPON1with PON1a, VCAM-1,
ICAM-1 and NO2-. For each biomarker, a univariable analysis
was performed considering age, sex, co-morbidities, total
cholesterol, HDL, LDL, triglycerides and each binary variable
resulting from the positive antibody titers cut-off (176.84%
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for IgG aHDL, 0.28μg/mL for aApoA-I and 311.7% for aPON1
antibodies): variables with p-value of < 0.25 were consi-
dered for the multivariable study.
First, three multivariable regression models considered
the log of PON1a as dependent variable and age, co-morbid-
ities, HDL, LDL and dichotomized antibody titers (positive vs.
negative) separately, as independent variables. IgG aHDL,
aApoA-I or aPON1 higher than the cut-off of positivity
negatively predicted PON1a corresponding to a decrease of
17.63% ( ¼ –0.194, p ¼ 0.020), 31.82% ( ¼ –0.383,
p < 0.001) and 25.77% ( ¼ –0.298, p ¼ 0.007), respectively,
when compared with lower antibody titers (►Table 3).
Second, threemultivariable regressionmodels considered
the log of VCAM-1 as dependent variable and age, HDL, LDL
and dichotomized antibody titers separately as independent
variables. IgG aHDL, aApoA-I or aPON1 higher than the cut-
off of positivity independently predicted VCAM-1 by 42.19%
( ¼ 0.352, p < 0.001), 44.05% ( ¼ 0.365, p < 0.001) and
51.89% ( ¼ 0.418, p ¼ 0.001), respectively, when compared
with lower antibodies titers (►Table 3).
Lastly, three multivariable regression models considered
the log of ICAM-1 as dependent variable and age, sex, co-
morbidities, HDL, LDL, triglycerides and dichotomized anti-
body titers separately as independent variables. Results
Table 2 Biologic variables of the healthy controls and patients with atherosclerosis-associated clinical events
Characteristics,
median (IQR)
Healthy controls
(n ¼ 55)
IS (n ¼ 53) p-Valuea CAD (n ¼ 51) p-Valueb
Cholesterol (mg/dL) 148.50 (114.00–192.75) 160.00
(107.75–200.00)
0.258 137.50
(104.00–159.00)
0.989
HDL (mg/dL) 49.71 (38.75–67.28) 38.5 (26.50–46.50) < 0.001 32.00
(26.50–44.25)
< 0.001
LDL (mg/dL) 79.00 (45.85–105.96) 104.00
(73.50–138.50)
0.001 93.50
(67.75–108.50)
0.099
Triglycerides
(mg/dL)
85.00 (63.00–149.50) 116.00
(96.00–149.50)
< 0.001 99.50
(72.50–140.80)
0.030
IgG aHDL
(% p. control)
87.82 (68.23–105.80) 150.22
(104.11–220.20)
< 0.001 149.26
(111.40–205.60)
< 0.001
IgM aHDL
(% p. control)
34.49 (19.42–63.69) 23.99 (9.66–55.72) 0.223 22.86
(17.23–47.18)
0.497
IgG aApoA-I
(µg/mL)
0.09 (0.07–0.14) 0.22 (0.14–0.36) < 0.001 0.21
(0.14–0.38)
< 0.001
IgG aApoA-II
(% p. control)
116.70 (63.02–182.80) 121.50
(95.71–195.20)
0.436 171.50
(83.62–222.00)
0.209
IgG aApoC-I
(% p. control)
242.50 (157.00–362.50) 242.90
(116.40–394.80)
0.891 250.70
(105.80–541.70)
0.872
IgG aPON1
(% p. control)
70.59 (39.83–144.12) 121.95
(82.99–201.40)
< 0.001 155.93
(70.98–305.90)
< 0.001
PON1a (U/L) 310.41 (236.62–333.05) 203.95
(146.29–272.74)
< 0.001 166.60
(119.50–278.70)
< 0.001
TAC (VEA-equivalent
units, μM)
7.66 (6.06–9.05) 8.06 (6.71–9.42) 0.716 8.38
(6.55–10.79)
0.188
VCAM-1 (ng/mL) 606.14 (501.95–710.75) 1100.18
(683.55–1411.19)
< 0.001 1360.15
(1016.00–2146.00)
< 0.001
ICAM-1 (ng/mL) 297.94 (251.88–334.05) 333.18
(288.43–404.99)
0.005 404.36
(348.20–595.70)
< 0.001
NO2
- (μM) 12.06 (6.63–19.78) 8.38 (5.86–12.04) 0.076 7.19
(5.11–11.50)
0.028
NO3
- (μM) 23.26 (11.55–30.95) 16.19 (7.56–29.49) 0.153 27.89
(13.92–51.45)
0.192
3-NT (nM) 17.42 (14.91–21.21) 17.49
(15.98–21.45)
0.296 17.48
(15.84–19.62)
0.083
Abbreviations: 3-NT, 3-nitrotyrosine; aApoA-I, anti-apolipoprotein A-I antibodies; aApoA-II, anti-apolipoprotein A-II antibodies; aApoC-I,
anti-apolipoprotein C-I antibodies; aHDL, anti-HDL antibodies; ANOVA, analysis of variance; aPON1, anti-paraoxonase 1 antibodies; CAD, coronary
artery disease; HDL, high-density lipoprotein; ICAM-1, intercellular adhesion molecule 1; IgG, immunoglobulin G; IgM, immunoglobulin M;
IQR, interquartile range; IS, ischaemic stroke; LDL, low-density lipoprotein; NO2, nitrite; NO3, nitrate; PON1a, paraoxonase 1 activity;
TAC, total antioxidant capacity; VCAM-1, vascular cell adhesion molecule 1; VEA, vitamin E analogue.
Note: SI conversions: To convert total LDL and HDL and total cholesterol to mmol/L, multiply by 0.0259; and to convert triglycerides to mmol/L,
multiply by 0.0113.
aComparison between the healthy control and ischaemic stroke (IS) group.
bComparison between the healthy control and coronary artery disease (CAD) group. p-Value obtained by one-way ANOVA applied to log-transformed data.
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showed that only IgG aApoA-I and aPON1 higher than the
cut-off of positivity independently predicted higher ICAM-1
levels of 14.68% ( ¼ 0.137, p ¼ 0.035) and 35.39%
( ¼ 0.303, p < 0.001), respectively, when compared with
lower antibody titers (►Table 3). No association was
observed between NO2- levels and the antibody titers.
Incremental Value of Adding the HDL Auto-Antibody
Proﬁle to a Lipid Atherosclerotic Disease Risk
Prediction Model
By using univariable logistic regression analysis, we explored
which CV risk factors (age, sex, co-morbidities, total choles-
terol, HDL, LDL, triglycerides) were related to HDL antibo-
dies: those with a p-value of < 0.25 were considered for the
multivariable study.
In IS, age, HDL and LDL levels remained the same in the
multivariable model (IS reference model). By adding sepa-
rately each antibody titer in IS patients (IgG aHDL, aApoA-I or
aPON1 antibodies), a 10% increment of IgG aHDL, 0.04 ug/mL
of aApoA-I or 10% of aPON1 raised the odds of having IS
( ¼ 1.47, 95% CI ,1.20–1.81, p < 0.001; ¼ 1.35, 95% CI,
1.16–1.58, p < 0.001; ¼ 1.11, 95% CI, 1.03–1.19,
p ¼ 0.005, respectively) (►Table 4).
In CAD, age and HDL levels remained the same in the
multivariable model (CAD reference model). By adding sepa-
rately each antibody titers, a 10% increment of IgG aHDL, 0.04
ug/mL of aApoA-I or 10% of aPON1 raised the odds of having
CAD ( ¼ 1.61, 95% CI, 1.21–2.14, p ¼ 0.001; ¼ 1.16,
95% CI, 1.02–1.32, p ¼ 0.028; ¼ 1.11, 95% CI, 1.02–1.20,
p ¼ 0.015, respectively) (►Table 4).
With regards to calibration, all models had a good per-
formance (Hosmer-Lemeshow test p-value ¼ 0.106, 0.885,
0.998 and 0.871 respectively, for reference model, reference
model plus aHDL, plus aApoA-I or plus aPON1 antibodies) in
patients with IS as in patients with CAD (Hosmer-Lemeshow
test p-value ¼0.978, 0.758, 0.999 and 0.740, respectively for
the same models) (►Table 5).
With regards to the discriminative ability of the models,
we obtained acceptable to outstanding AUC values26 for the
reference model, reference model plus IgG aHDL, reference
Fig. 1 Levels of antibodies against high-density lipoprotein (aHDL) complex. Immunoglobulin G (IgG) aHDL (A), anti-apolipoprotein A-I (aApoA-I) (B) and
paraoxonase-1 activity (aPON1) (C) antibodies in healthy controls and patients with atherosclerosis-associated clinical events: ischaemic stroke (IS) and
coronary artery disease (CAD). Bars show the median with interquartile range. p-Value of < 0.001 for both IS and CAD patients when compared with
healthy controls.
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model plus IgG aApoA-I or referencemodel plus IgG aPON1 in
IS and CAD (►Table 5). Moreover, only the models resulting
from adding IgG aHDL or aApoA-I in IS and IgG aHDL in CAD
had statistically different AUCs from the reference model
(p ¼ 0.006, p < 0.001 and p ¼ 0.021, respectively).
To further quantify the improvement resulting from
adding IgG aHDL, aApoA-I or aPON1 to the reference
model, we calculated category-free net re-classiﬁcation
improvement (NRI) and integrated discrimination improve-
ment (IDI) measures with corresponding bootstrap of 95%
CIs. The NRI quantiﬁes the correctness of upward and
downward movement of predicted probabilities resulting
from adding the three referred antibodies to the reference
model. The IDI measures the size of changes in these
probabilities.27
For IS, according to NRI events and non-events (45.8%, 95%
CI, 16.2–71.4 and 73.1%, 95% CI, 45.6–87.8, respectively) and
according to IDI events and non-events (0.115, 95% CI, 0.058–
0.230 and 0.114, 95% CI, 0.053–0.211, respectively), adding
IgG aHDL to the referencemodel resulted in an improvement
in identifying patients with an increased CV risk (►Table 5).
A similar improvement in classifying patients with CAD
was observed by adding IgG aHDL antibodies to the reference
model according to NRI events and non-events (65.2%, 95%
CI, 16.3–85.7 and 73.6%, 95% CI, 25.0–88.9, respectively), and
IDI events and non-events (0.101, 95% CI, 0.044–0.190 and
0.086, 95% CI, 0.041–0.163, respectively) (►Table 5).
For patients with IS, the change in identifying patients
with increased CV risk from adding IgG aApoA-I to the
reference model resulted in an improvement of NRI events
Table 3 Multivariable linear regression models to study the association between PON1 activity, VCAM-1, ICAM-1 and NO2
- levels
and IgG aHDL, aApo A-I and aPON1 antibodies
Variablesa Log PON1a Log VCAM-1 Log ICAM-1 Log NO2-
(95% CI) p-Value (95% CI) p-Value (95% CI) p-Value (95% CI) p-Value
IgG aHDL
Age –0.011
(–0.016 to 0.005)
< 0.001 0.019
(0.013–0.024
< 0.001 0.007
(0.003–0.011)
< 0.001 –0.015
(–0.024 to 0.007)
0.001
LDL 0.002
(0.001–0.004)
0.011 –0.002
(–0.004 to 0.000)
0.04   –0.004
(–0.007 to 0.001)
0.013
Triglyceride       0.003
(0.001–0.005)
0.008
HDL 0.004
(0.000–0.0008)
0.038 –0.007
(–0.011 to 0.002)
0.002 –0.005
(–0.007 to 0.002)
0.001  
IgG aHDL
> cut-off þ
–0.194
(–0.357 to 0.031)
0.020 0.352
(0.175–0.529)
< 0.001 0.076
(–0.043 to 0.195)
0.210 –0.203
(–0.493 to 0.087)
0.169
IgG aApoA-I
Age –0.010
(–0.015 to 0.005)
< 0.001 0.017
(0.012–0.023)
< 0.001 0.007
(0.003–0.011)
< 0.001 –0.015
(–0.024 to 0.007)
0.001
LDL       –0.004
(–0.007 to 0.001)
0.013
Triglyceride       0.003
(0.001–0.005)
0.008
HDL   –0.005
(–0.010 to 0.001)
0.008 –0.003
(–0.006 to 0.001)
0.018  
IgG aApoA-I
> cut-off þ
–0.383
(–0.545 to 0.222)
< 0.001 0.365
(0.182–0.549)
< 0.001 0.137
(0.009–0.265)
0.035 –0.201
(–0.507 to 0.105)
0.195
IgG aPON1
Age –0.010
(–0.016 to 0.005)
< 0.001 0.017
(0.011 to 0.023)
< 0.001 0.007
(0.003–0.010)
0.001 –0.015
(–0.024 to 0.007)
0.001
Co-morbidities –0.175
(–0.326 to 0.024)
0.023   0.133
(0.033–0.232
0.009  
LDL 0.002
(0.001–0.004)
0.009     –0.004
(–0.007 to 0.001)
0.013
Triglyceride       0.003
(0.001–0.005)
0.008
HDL   –0.006
(–0.010 to 0.002)
0.005    
IgG aPON1
> cut-off þ
–0.298
(–0.513 to 0.083)
0.007 0.418
(0.185–0.651)
0.001 0.303
(0.159–0.447)
< 0.001 –0.336
(–0.703 to 0.030)
0.072
Abbreviations: , regression coefﬁcient estimate; aApoA-I, anti-apolipoprotein A-I antibodies; aHDL, anti-HDL antibodies; aPON1, anti-paraoxonase 1
antibodies; CI, conﬁdence interval; HDL, high-density lipoprotein; ICAM-1, intercellular adhesion molecule 1; IgG, immunoglobulin G; LDL,
low-density lipoprotein; Log, natural logarithm; NO2
-, nitrite; PON1a, paraoxonase 1 activity; TAC, total antioxidant capacity; VCAM-1, vascular cell
adhesion molecule 1.
aAll variables that were not statistically signiﬁcant in each multivariable model were excluded, with the exception of the antibodies titers.
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and non-events (54.2%, 95% CI, 21.5–77.1 and 80.4%, 95% CI,
54.5–92.9, respectively) and IDI events and non-events
(0.148, 95% CI, 0.063–0.245 and 0.134, 95% CI, 0.066–0.230,
respectively) (►Table 5). However, for patients with CAD
adding IgG aApoA-I antibodies to the reference model
resulted in a negligible change of NRI events and non-events
and IDI events and non-events (►Table 5). For both groups of
patients, the change in identifying those with an increased
CV risk after adding IgG aPON1 to the reference model was
also negligible as reﬂected by the low values of NRI events
and non-events and IDI events and non-events (►Table 5).
Isolation of IgG aHDL Antibodies by Immunoafﬁnity
Chromatography
►Supplementary Fig. S1 (available in the online version)
shows a typical elution proﬁle of IgG aHDL from patient
serum. All the collected fractions were tested for the pre-
sence of IgG aHDL (►Supplementary Fig. S2A, available in the
online version). The recovery of IgG aHDL from the column
was greater than 90% and the puriﬁed IgG aHDL retained the
ability to bind to human HDL (►Supplementary Fig. S2B,
available in the online version).
IgG aHDL Inhibition of PON1 Activity In Vitro
IgG aHDL puriﬁed from patients inhibited PON1a in a dose-
dependent fashion from 12 to 38% (p < 0.01, ►Fig. 2A). The
non-speciﬁc human IgG used as control did not inﬂuence
PON1a.
IgG aHDL Antibodies Abolish the Protecting Effect of
HDL on Endothelial Activation
Unstimulated HUVECs do not express VCAM-1 but they
express it after exposure to an inﬂammatory stimulus such
as TNF-α; indeed, we observed a 250.40  77.79% up-reg-
ulation of VCAM-1 expression as compared with baseline.
The pro-inﬂammatory effect of TNF-α was prevented by the
pre-incubation of HUVECswithHDL (69.97  42.79%VCAM-
1 expression), which led to a marked reduction of 72% in the
subsequent expression of VCAM-1 (p < 0.001). In contrast,
the addition of puriﬁed IgG aHDL to the culture system
increased VCAM-1 expression to 175.80  27.43% and abro-
gated the inhibitory effect of HDL on VCAM-1 expression by
more than 126% (p < 0.001). The incubation of HDL with
non-speciﬁc human IgG did not abolish the anti-inﬂamma-
tory effect of HDL. Moreover, the addition of recombinant
human IgG aApoA-I prevented the protective effect of HDL on
VCAM-1 expression by 112% (VCAM-1 expression,
156.60  32.36%; p ¼ 0.02) (►Fig. 2B). The presence of IgG
aHDL antibodies alone or with TNF-α did not modify the
expression of VCAM-1 on HUVECs.
Discussion
The novel and important ﬁndings of our study is the detec-
tion of IgG aHDL antibodies, in particular, aPON1 antibodies,
in non-autoimmunepatients and the conﬁrmation of aApoA-
I in patients with stable chronic IS and CAD. In addition,
this is theﬁrst study to simultaneously determine antibodies
against HDL (IgG and IgM) in general and against differ-
ent HDL components (ApoA-I, PON1, ApoA-II, ApoC-I) in
particular.
In previous reports, IgG aHDL, aApoA-I and aPON1 were
associated with decreased PON1a, endothelial activation,
increased disease-related CV damage and activity in patients
with autoimmune diseases10–14,16 and were considered an
early biomarker of premature atherosclerosis in SLE15; at
Table 4 Multivariable logistic regression models to study the incremental value of adding IgG aHDL, aApo A-I or aPON1 antibodies
to traditional cardiovascular risk factors in patients with atherosclerosis-associated clinical events
Variable Reference model (RM) RM þ IgG aHDL RM þ IgG aApoA-I RM þ IgG aPON1
¼ (95% CI) p-Value ¼ (95% CI) p-Value ¼ (95% CI) p-Value ¼ (95% CI) p-Value
IS
Agea 1.04 (1.00–1.08) 0.052 1.08 (1.02–1.14) 0.007 1.05 (1.00–1.11) 0.070 1.04 (1.00–1.08) 0.065
HDL 0.94 (0.91–0.97) 0.001 0.93 (0.89–0.98) 0.010 0.94 (0.90–1.00) 0.041 0.95 (0.91–0.99) 0.007
LDL 1.02 (1.01–1.04 0.001 1.03 (1.01–1.05 0.007 1.04 (1.02–1.07) 0.001 1.03 (1.01–1.04 < 0.001
IgG aHDLa 1.47 (1.20–1.81) < 0.001
IgG aApoA-Ia 1.35 (1.16–1.58) < 0.001
IgG aPON1a 1.11 (1.03–1.19) 0.005
CAD
Agea 1.14 (1.08–1.21) < 0.001 1.17 (1.08–1.27) < 0.001 1.13 (1.07–1.20) < 0.001 1.15 (1.08–1.22) < 0.001
HDL 0.93 (0.89–0.97) 0.001 0.95 (0.90–1.00) 0.056 0.94 (0.90–0.99) 0.013 0.94 (0.90–0.99) 0.012
IgG aHDLa 1.61 (1.21–2.14) 0.001
IgG aApoA-Ia 1.16 (1.02–1.32) 0.028
IgG aPON1a 1.11 (1.02–1.20) 0.015
Abbreviations: , odds ratio estimate; aApoA-I, anti-apolipoprotein A-I antibodies; aHDL, anti-HDL antibodies; aPON1, anti-paraoxonase 1
antibodies; CAD, coronary artery disease; CI, conﬁdence interval; HDL, high-density lipoprotein; IgG, immunoglobulin G; IS, ischaemic stroke; LDL,
low-density lipoprotein; RM, reference model.
aAge, IgG aHDL, aApoA-I and aPONI1 antibodies’ odds ratios were estimated for each increase of 1 year, 10%, 0.04 ug/mL and 10%, respectively.
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variance, IgG aApoA-I predicted a poorer outcome in patients
with acute IS,18 were associated with CVD in the general
population19 being linked to plaque vulnerability20,28 and
bore prognostic relevance in myocardial infarction.21,29
This studyalsomeasured IgMaHDL antibodies for theﬁrst
time, although both patient groups presented non-signiﬁ-
cant lower average levels than controls as opposed to what
we observed for IgG aHDL. Additional average levels of IgM
aHDL antibodies were much lower than IgG aHDL levels in
the three groups, which is in line with the concept that upon
chronic (repeated) antigen exposure, the IgM response is
usually absent or relatively low as compared with the sec-
ondary antibody response. We cannot exclude that IgG
antibodies have greater afﬁnities than IgM antibodies and
often out-compete them for antigens, making it difﬁcult to
reliably measure IgM levels.
Taken together, our data suggest that aHDL represents a
new family of auto-antibodies, in a similar fashion to the
anti-nuclear antibodies (ANA), which are present in many
autoimmune diseases. The strong correlation between IgG
aHDL, aApoA-I and aPON1 titers suggests that ApoA-I and
PON1 might be the key targets, rather the lack of a positive
titer of IgG aApoA-II and IgG aApoC-I across the two study
groups rules against ApoA-II and ApoC-I as relevant (auto)-
antigens within the HDL complex.
PON1 is the enzyme that accounts for most of the anti-
oxidant activity of HDL against LDL and a reduced activity
favours CVD30 and cerebrovascular disease31; in line with
Table 5 Improvement from adding IgG aHDL, aApoA-I or aPON1 antibodies to a reference model in patients with atherosclerosis-
associated clinical events
Variable Reference model (RM) RM þ IgG aHDL RM þ IgG aApoA-I RM þ IgG aPON1
IS
Goodness-of-ﬁt
(Hosmer–Lemeshow test)
0.106 0.885 0.998 0.871
AUC 0.79 (0.63–0.85) 0.89 (0.81–0.93) 0.92 (0.85–0.96) 0.83 (0.72–0.89)
p-Value (AUC difference) ¼ 0.006 < 0.001 ¼ 0.063
cfNRI, % (CI)
cfNRI events 45.8 (16.2–71.4) 54.2 (21.5–77.1) 4.2 (–14.6 to 40.5)
p-Value < 0.001 < 0.001 ¼ 0.562
cfNRI non-events 73.1 (45.6–87.8) 80.4 (54.5–92.9) 34.6 (9.0–66.7)
p-Value < 0.001 < 0.001 ¼ 0.008
IDI, (CI)
IDI events 0.115 (0.058–0.230) 0.148 (0.063–0.245) 0.047 (0.009–0.117)
IDI non-events 0.114 (0.053–0.211) 0.134 (0.066–0.230) 0.044 (0.008–0.103)
IDI 0.229 (0.117–0.421) 0.282 (0.135–0.462) 0.091 (0.016–0.214)
p-Value < 0.001 < 0.001 < 0.001
CAD
Goodness-of-ﬁt
(Hosmer–Lemeshow test)
0.978 0.758 0.999 0.740
AUC 0.90 (0.82–0.94) 0.96 (0.90–0.98) 0.92 (0.87–0.97) 0.92 (0.85–0.95)
p-Value (AUC difference) ¼ 0.021 ¼ 0.160 ¼ 0.310
cfNRI, % (CI)
cfNRI events 65.2 (16.3–85.7) 17.4 (–11.8 to 62.8) 11.1 (–14.9 to 47.6)
p-Value < 0.001 ¼ 0.120 ¼ 0.453
cfNRI non-events 73.6 (25.0–88.9) 19.2 (–27.3 to 71.4) 39.6 (–3.9 to 76.1)
p-Value < 0.001 ¼ 0.087 ¼ 0.070
IDI, (CI)
IDI events 0.101 (0.044–0.190) 0.030 (0.000–0.087) 0.041 (0.006–0.105)
IDI non-events 0.086 (0.041–0.163) 0.026 (0.003–0.076) 0.030 (0.004–0.080)
IDI 0.187 (0.086–0.346) 0.056 (0.003–0.154) 0.071 (0.011–0.186)
p-Value < 0.001 ¼ 0.080 ¼ 0.003
Abbreviations: aApoA-I, anti-apolipoprotein A-I antibodies; aHDL, anti-HDL antibodies; aPON1, anti-paraoxonase 1 antibodies; AUC, area under the
receiver operating characteristic curve; CAD, coronary artery disease; cfNRI, category-free net reclassiﬁcation improvement; CI, conﬁdence interval;
HDL, high-density lipoprotein; IDI, integrated discrimination improvement; IgG, immunoglobulin G; IS, ischaemic stroke.
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these studies, our CAD and IS patients showed a 50 and 35%
decrease of PON1a, respectively. Our regression model
demonstrates that the greater than the cut-off of positivity
of IgG aHDL, aApoA-I and aPON1 were signiﬁcant predictors
of the impaired PON1a with respective decrements of 17.63,
31.82 and 25.77%. Furthermore, our in vitro experiments
showed that the IgG aHDL isolated from patients inhibited
PON1a in a dose-dependent fashion. This may represent a
further mechanism by which IgG aApoA-I and aPON1 may
contribute to the pro-oxidative state which is characteristic
of atherosclerosis.32
VCAM-1 and ICAM-1 mediate the recruitment of circulat-
ing leukocytes to the vessel wall and are important factors in
the early inﬂammatory and immune activation phases of
atherogenesis. Opinions vary when it comes to the clinical
relevance of plasma adhesion molecules; in healthy indivi-
duals, increased ICAM-1 is a signiﬁcant predictor of future
CAD events, whereas VCAM-1 is a signiﬁcant predictor of
future coronary events only in a sub-group of patients with
pre-existing CAD.33–36 In patients with IS, a plasma concen-
tration of VCAM-1 is related to an increased risk of recurrent
stoke.37 Indeed, both molecules were increased in our
patient groups: our regression models show that IgG aHDL,
aApoA-I or aPON1 titers greater than the cut-off of positivity
were signiﬁcant predictors of VCAM-1 increase, whereas
only IgG aApoA-I and aPON1 antibodies titers higher than
the cut-off of positivity, independently predicted ICAM-1
increase.
Our validation experiments in vitro showed that IgG aHDL
suppressed the HDL inhibition of VCAM-1 expression
induced by TNF-α in HUVECs and therefore monocyte adhe-
sion to endothelial cells, which preludes their transmigration
within the intima of the arterial vessels.38,39
Given these direct effects of IgG aHDL, we investigated
whether this family of antibodies were better predictors of IS
or CAD than the traditional CV risk factors. The incremental
value of adding separately each antibody titer to a traditional
CV risk factors model was shown by the increased ORs of
having IS or CAD, obtained for aHDL, aApoA-I and aPON1.
The addition of each antibody to the model results in a
signiﬁcant change in the goodness of ﬁt and in the AUCs
between the reference and the new models including the
antibodies. However, a good discriminative ability of the
models to predict between patients with IS or CAD and
healthy subjects was only observed with the addition of
aHDL and aApoA-I in patients with IS and the addition of
aHDL in patients with CAD. These additions yielded a correct
re-classiﬁcation which further improved the NRI and IDI.
This was not observed with the addition of aApoA-I anti-
bodies for patients with CAD or the addition of aPON1
antibodies in both groups of patients. In other words, the
addition of IgG aHDL and aApoA-I to the model provides a
more accurate diagnosis of IS and the addition of IgG aHDL
antibodies contributes to a more accurate diagnosis of CAD.
Our study has some limitations: (1) poor accrual of
participants leading to the age difference between patients
and controls that could partially confound relations,
although our statistical models accounted for this; (2) the
cross-sectional design that does not inform on causality
supported; however, this was accounted for by our in vitro
data; and (3) in the analyses regarding the incremental
prognostic value of the antibodies, the reference model
was adjusted for the traditional CV risk factor; however,
we could not use the CVD risk scoring system.
Fig. 2 Biologic activity of the anti-high-density lipoprotein (aHDL)
antibodies isolated from serum patients with atherosclerosis-associated
clinical events. (A) In vitro inhibition of paraoxonase-1 (PON1) activity by
aHDL antibodies isolated from serum patients with atherosclerosis-asso-
ciated clinical events (ischaemic stroke [IS] and coronary artery disease
[CAD]).Human immunoglobulinG (IgG)wasusedas control and0%effect is
the PON1 activity at basal conditions (HDL, 100 μg/mL). Differences
between means were evaluated using Bonferroni’s multiple comparison
test. p-Value of < 0.01 with reference to IgG at the same concentration.
(B) Effect of aHDL antibodies isolated from patients serum on vascular cell
adhesion molecules 1 (VCAM-1) expression in human umbilical vein
endothelial cells (HUVECs) exposed to tumournecrosis factor-alpha (TNF-α).
Conﬂuent cultures HUVECs were incubated in basal condition (0% effect),
human HDL (1.0 mg/mL), TNF-α (10 ng/mL), HDL þ TNF-α alone or with
aHDL antibodies (50 μg/mL) isolated from serum patients with
atherosclerosis-associated clinical events or a non-speciﬁc human IgG
(50μg/mL) or commercial human anti-apolipoprotein A-I (ApoA-I) mono-
clonal antibody (30 μg/mL). Bars show the means  standard deviation
(SD). Differences between means were evaluated using a Kruskal–Wallis
test. p-Valueof < 0.001and p ¼ 0.002with reference toHDL þ TNF-α.
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The presence of either IgM or IgG antibodies towards HDL
components may allow the formation of IgM/IgG aHDL/HDL
complex and their removal: this may partly explain why
many patients have low levels of HDL andwhy others remain
at risk for clinical events despite having normal HDL levels.
On that note, these antibodies may explain the recent failure
of drugs meant to increase HDL to improve clinical
outcomes.24
In clinical practice and in clinical trials, quantiﬁcation of
total HDL is still a test of choice because of ease of determi-
nation, reproducibility and affordability: unfortunately, the
measurement ofHDL does not informon its functionality and
tests assessing the latter do not currently exist, but measure-
ment of IgG against HDL components may provide indirect
information.
In conclusion, IgGantibodies againstHDL components are a
new family of auto-antibodies that interfere with some anti-
atherogenic functionsofHDLcontributinganother pieceto the
mosaic where atherosclerosis is depicted as an autoimmune
disease. Prospective studies are required to assess the prog-
nostic value of anti-HDL antibodies and eventually re-deﬁne
the treatment strategies having HDL as their target.
What is known about this topic?
• IgG aHDL, aApoA-I and aPON1 antibodies are present
in autoimmune diseases in association with decreased
PON1 activity, endothelial activation, disease activity
and cardiovascular damage.
• IgG aApoA-I antibodies relate to top atherosclerotic
plaque vulnerability with acute coronary syndrome,
have negative prognostic value in myocardial infarc-
tion and predict worse post-stroke outcomes.
• IgG aApoA-I antibodies have been shown to hamper
the protective effect of increase in HDL, suggesting an
explanation for the recent failure of drugs meant to
increase HDL to improve clinical outcomes.
What does this paper add?
• IgG aHDL, aApoA-I and aPON1 antibodies represent a
new family of auto-antibodies present in IS and CAD.
• IgG aHDL and aApoA-I antibodies provide greater
diagnostic accuracy for CAD and IS.
• IgG aHDL, aApoA-I and aPON1 antibodies interfere
with some anti-atherogenic functions of HDL.
• Testing for this new auto-antibody family might be an
indirect way of assessing HDL functionality.
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